0.00Open0.50Pre Close0 Volume0 Open Interest0.50Strike Price0.00Turnover0.00%IV-18.70%PremiumJul 19, 2024Expiry Date0.73Intrinsic Value100Multiplier-5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.46Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Adaptimmune Therapeutics Stock Discussion
Adaptimmune Therapeutics plc, a company in T-cell therapies, and Galapagos NV, recognized for its innovative approaches to drug discovery and development, have announced a clinical collaboration agreement. This partnership focuses on the exclusive licensing option for Adaptimmune's TCR T-cell therapy candidate, uza-cel, specifical...
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade.
(Type of Cancer) Synovial Sarcoma : There are more than 50 different types of soft tissue sarcomas which are categorise...
No comment yet